Navigation Links
Mylan Confirms Four First-to-File Challenges
Date:3/26/2009

PITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it and/or a subsidiary have been sued in connection with four separate "first-to-file" Abbreviated New Drug Applications (ANDA) filed with the U.S. Food and Drug Administration (FDA).

Mylan and Alphapharm Pty. Ltd were sued by Sepracor Inc. in the U.S. District Court of New Jersey in connection with the ANDA filing for Eszopiclone Tablets, 1 mg, 2 mg and 3 mg. Eszopiclone Tablets are the generic version of Sepracor's insomnia treatment Lunesta(R) Tablets, which had approximately $796 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan Pharmaceuticals Inc. was sued by OSI Pharmaceuticals Inc., Pfizer Inc. and Genentech Inc. in the U.S. District Court in Delaware in connection with the ANDA filing for Erlotinib Hydrochloride (HCl) Tablets, 25 mg, 100 mg and 150 mg. Erlotinib HCl Tablets are the generic version of OSI Pharmaceuticals' lung cancer treatment Tarceva(R) Tablets, which had approximately $492 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan, Mylan Pharmaceuticals and Matrix Laboratories Limited, in which Mylan owns a majority interest, were sued by Shire Canada Inc., Shire International Licensing B.V. and Shire U.S. Inc. in the U.S. District Court for the Southern District of New York in connection with the ANDA filing for Lanthanum Carbonate Chewable Tablets, 500 mg, 750 mg and 1000 mg. Lanthanum Carbonate Chewable Tablets are the generic version of Shire's kidney disease treatment Fosrenol(R), which had approximately $108 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan Pharmaceuticals was sued by Galderma Laboratories Inc., Galderma Laboratories LP, The R
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
2. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
3. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
4. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
7. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
10. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
11. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... The US markets on Friday, September 19, ... Jones Industrial Average finished at 17,279.74, up 0.08% and ... S&P 500 finished the session 0.05% lower at 2,010.40. ... finished on a positive note. The S&P 500 Health ... 0.10%, with the index gaining 6.95% in the previous ...
(Date:9/22/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed ... that the United States Patent & Trademark Office (USPTO) issued ... September that is part of a standard essential family of ... , Application number: US 13/728,867 , Publication date: ... The listed inventors of the new patent, ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Chemical ... global challenges such as clean air and safe ... and natural products. Chemists, environmentalists, food scientists, educators, ... the research in the field of Chemistry for ... Chemical Sciences is one of the fastest emerging ...
(Date:9/20/2014)... Netherlands (PRWEB) September 20, 2014 ... technologies to perform a groundbreaking surgery at the specialized ... the mare's superficial digital flexor tendon was ruptured 90% ... kind of injury is a death sentence for a ... America stem cell treatments . This revolutionary ...
Breaking Biology Technology:Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... , Baltimore Convention Center ... BALTIMORE, Aug. 11 This summit will attract more than 1,200 ... It will feature more than 100 speakers, including governors, federal officials, ... cell policies, scientific breakthroughs, and human-interest stories. This is your ...
... , SAN FRANCISCO, Aug. 11 ... stage biopharmaceutical company developing a proprietary breakthrough class of targeted ... private placement financing with gross proceeds of US $5,123,521, exceeding ... anticipated on or before September 15, 2009, with additional proceeds ...
... 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... to improving health through the development, manufacture and,commercialization of ... ("OTC"),products in China, announced today that the Audit Committee ... of Ernst & Young Hua Ming ("EY") as,the Company,s ...
Cached Biology Technology:World Stem Cell Summit to Be Held in Baltimore 2Jennerex Closes $5 Million First Tranche of Series C Financing 2
(Date:9/21/2014)... protein therapy that disrupts the process that causes cancer ... through the blood stream and start aggressive new growths ... metastasis, can cause cancer to spread with deadly effect. ... cancer fall prey to metastatic forms of the disease," ... describes a new therapeutic approach in Nature Chemical ...
(Date:9/19/2014)... University of Oklahoma biology professor will study multifunctional ... leg movements with a National Science Foundation grant ... project. , Ari Berkowitz, professor in the Department ... will focus on the differences between the multifunctional ... what neurotransmitters they use and what connections they ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... LA Research led by Lauren Cole, a public ... of Public Health and Director of the Epidemiology Program ... the incidence of head and neck cancer has risen ... with the greatest increase among middle-aged white men. At ...
... gene called XRCC2 cause increased breast cancer risk, according to ... Human Genetics . The study looked at families that have ... in the currently known breast cancer susceptibility genes. Sean ... professor in the Department of Oncological Sciences at the University ...
... such as the Iberian lynx, are under an increasingly serious ... that can even survive in extremely arid environments. A study ... to adapt according to climate. The life cycle of ... patterns of people and goods. These parasites and the pathogens ...
Cached Biology News:LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2A new breast cancer susceptibility gene 2Ticks can adapt to the Spain's climatic diversity 2
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Maize microRNA Microarray contains ...
... LTQ XL extends the legendary MSn performance ... generate structural information through Thermo Scientifics innovations ... LTQ XL is the only mass spectrometer ... and CID. Pulsed Q Collision Induced ...
... is a rugged, compact, lab-quality ... information you need - at ... of gas mixtures is critical, ... generates more data in less ...
... PolarScreen Peroxisome Proliferator-Activated Receptor-gamma (PPARGamma) ... sensitive and efficient method for ... ligands using fluorescence polarization (FP). ... binding domain (PPARGamma-LBD) with an ...
Biology Products: